MIN-117 (known formerly as WF-516) is an investigational antidepressant which is under development by Minerva Neurosciences for the clinical treatment of major depressive disorder (MDD).

[2][3][4] It is described as a 5-HT1A and 5-HT2A receptor antagonist and inhibitor of serotonin and dopamine reuptake,[4][5][6] and is also reported to possess affinity for the α1A- and α1B-adrenergic receptors.

[4][6] As of May 2015, MIN-117 is in phase II clinical trials for MDD.

[3] In December 2019, Minerva announced that MIN-117 was no longer in clinical development for MDD after disappointing results in a phase IIb trial.

[7] This drug article relating to the nervous system is a stub.